IMCR News and Press, Immunocore Holdings plc From 03/09/22

Immunocore to present at Oppenheimer’s 32 nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering th...

Immunocore press release (NASDAQ:IMCR): FY GAAP EPS of -$4.19 misses by $0.18. Revenue of $35.8M (-12% Y/Y). For further details see: Immunocore GAAP EPS of -$4.19 misses by $0.18, revenue of $35.8M

PRESS RELEASE Immunocore Reports Full Year 202 1 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp- tebn ) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma ; ...

Immunocore (NASDAQ:IMCR) said a committee of the European Medicines Agency (EMA) recommended the approval of its drug Kimmtrak (tebentafusp) to treat  HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), a type of cancer affecting the eye. The re...

P RESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK ® ( tebentafusp ) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will b...

Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the developme...

Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresect...

Immunocore to present at the 40 th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the dev...

Immunocore a nnounces i nitial Phase 1 d ata of ImmTAC ® candidate I MC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC M ...

P RESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pi...